|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating expenses | |||||
| Research and development | |||||
| General and administrative | |||||
| Goodwill impairment | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income, net | |||||
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | |||||
| Change in fair value of warrant liabilities | |||||
| Loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Unrealized loss on available-for-sale securities, net | |||||
| Comprehensive loss | |||||
| Basic earnings per share of common stock | |||||
| Series X and Series X1 Non-voting Convertible Preferred Stock | |||||
| Total basic earnings per share of common stock | |||||
| Diluted earnings per share of common stock | |||||
| Series X and Series X1 Non-voting Convertible Preferred Stock | |||||
| Total diluted earnings per share of common stock | |||||
| Weighted-average common shares outstanding, basic | |||||
| Series X and Series X1 Non-voting Convertible Preferred Stock | |||||
| Total weighted-average common shares outstanding, basic | |||||
| Weighted-average common shares outstanding, diluted | |||||
| Series X and Series X1 Non-voting Convertible Preferred Stock | |||||
| Total weighted-average common shares outstanding, diluted | |||||
Loading...